Thyroid eye disease (TED) therapy Tepezza – the very best asset in Amgen's $26 billion takeover of Horizon in 2023 – can be facing Levels of competition from A neater-to-dose alternate from Sling Therapeutics. Zeidan was Formerly the chief development officer at Millendo Ther